Spanish biotechnology company Midatech Biogune is using Syrris Atlas Potassium reactor systems to produce custom-made gold nanoparticles for medicinal use.
Midatech chief executive officer Justin Barry said: “Midatech is a clinical stage biotechnology company focused on translating its proprietary gold nanoparticle drug delivery platform into effective nanomedicines targeting currently unmet medical needs.
“We begin by producing functionalised gold nanoparticles on a bench scale, then move to larger scale manufacturing processes, where it makes sense to use a reactor system. Our Atlas Potassium reactors, with pH control and an Atlas Syringe Pump XL, have allowed us to scaleup production, enabling variables such as pH and temperature to be tightly controlled.”
Barry added: “The Atlas Potassium was the only logical way to move from manufacturing nanoparticles on a laboratory scale to a mini production environment. It is a reliable and reproducible reactor system that is well assembled, compact and portable, and performs exactly as we were told it would.
“Atlas Potassium is also very flexible, accommodating volumes ranging from 50 ml to 2 litres. Its operating software works well, enabling a series of validation runs to be performed quickly and easily. The Atlas reactors were easy to implement in the laboratory, and it took just six to eight months to establish a validated process. We are very happy with them.”
